{"id":"mp0420","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MP0420 binds to programmed death receptor 1 (PD-1) on the surface of T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the inhibitory signal that tumors use to evade immune attack, thereby restoring T cell activation, proliferation, and anti-tumor cytotoxic function.","oneSentence":"MP0420 is a monoclonal antibody that targets and blocks PD-1 on T cells to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:12.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT04828161","phase":"PHASE2, PHASE3","title":"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-10","conditions":"COVID-19","enrollment":407},{"nctId":"NCT05780463","phase":"PHASE3","title":"MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-06-11","conditions":"COVID-19","enrollment":485},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT04870164","phase":"PHASE1","title":"Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)","status":"TERMINATED","sponsor":"Molecular Partners AG","startDate":"2020-11-18","conditions":"COVID-19","enrollment":53},{"nctId":"NCT04834856","phase":"PHASE2","title":"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients","status":"COMPLETED","sponsor":"Molecular Partners AG","startDate":"2021-04-01","conditions":"Covid19","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ensovibep"],"phase":"phase_3","status":"active","brandName":"MP0420","genericName":"MP0420","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MP0420 is a monoclonal antibody that targets and blocks PD-1 on T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}